Gliomatosis cerebri medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[Radiotherapy]] and [[chemotherapy]] are recommended among all patients who develop gliomatosis cerebri. [[Temozolomide]] and [[PCV regimen|PCV 3 combination chemotherapy]] are the preferred drugs for the treatment of high-grade and low-grade gliomatosis cerebri, | [[Radiotherapy]] and [[chemotherapy]] are recommended among all patients who develop gliomatosis cerebri. [[Temozolomide]] and [[PCV regimen|PCV 3 combination chemotherapy]] are the preferred drugs for the treatment of high-grade and low-grade gliomatosis cerebri, respectivel Supportive therapy for gliomatosis cerebri includes [[anticonvulsants]] and [[corticosteroids]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
The | The medical therapy of gliomatosis cerebri includes: | ||
===1. Radiotherapy=== | ===1. Radiotherapy=== | ||
*[[Radiation|Post-operative radiotherapy]] is recommended among all patients who develop gliomatosis cerebri.<ref name="pmid21301914">{{cite journal| author=Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T| title=Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. | journal=Neurosurg Rev | year= 2010 | volume= 34 | issue= 2 | pages= 197-208 | pmid=21301914 | doi=10.1007/s10143-010-0306-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21301914 }} </ref> | *[[Radiation|Post-operative radiotherapy]] is recommended among all patients who develop gliomatosis cerebri.<ref name="pmid21301914">{{cite journal| author=Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T| title=Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. | journal=Neurosurg Rev | year= 2010 | volume= 34 | issue= 2 | pages= 197-208 | pmid=21301914 | doi=10.1007/s10143-010-0306-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21301914 }} </ref> | ||
| Line 41: | Line 41: | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Neurosurgery]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
Latest revision as of 12:19, 25 October 2019
|
Gliomatosis cerebri Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gliomatosis cerebri medical therapy On the Web |
|
American Roentgen Ray Society Images of Gliomatosis cerebri medical therapy |
|
Risk calculators and risk factors for Gliomatosis cerebri medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Radiotherapy and chemotherapy are recommended among all patients who develop gliomatosis cerebri. Temozolomide and PCV 3 combination chemotherapy are the preferred drugs for the treatment of high-grade and low-grade gliomatosis cerebri, respectivel Supportive therapy for gliomatosis cerebri includes anticonvulsants and corticosteroids.
Medical Therapy
The medical therapy of gliomatosis cerebri includes:
1. Radiotherapy
- Post-operative radiotherapy is recommended among all patients who develop gliomatosis cerebri.[1]
- Radiotherapy may not cure the cancer but can control the tumor, delay recurrence, and increase survival.
- Radiation therapy is associated with temporary improvement of clinical symptoms.[2]
- External beam radiation therapy is preferred to whole brain radiotherapy.[3]
- The median dose of radiation is 60 Gy (range: 50-72 Gy).[1]
2. Chemotherapy
- Chemotherapy is indicated as adjuvant therapy for gliomatosis cerebri.
- Temozolomide (Temodar) is the preferred drug for the treatment of high-grade gliomatosis cerebri.[4][5]
- PCV 3 combination chemotherapy is the preferred drug regimen for slow growing, low-grade gliomatosis cerebri.[6]
- CCNU is administered on day 1, procarbazine is administered daily for 14 days beginning on day 8, and vincristine is administered on days 8 and 29 of each 6-week cycle of therapy.[7]
- Other chemotherapeutic drugs that may be used for the treatment of gliomatosis cerebri include:[8][9][10]
3. Supportive treatment
- Supportive therapy for gliomatosis cerebri includes anticonvulsants and corticosteroids, which focuses on relieving symptoms and improving the patient’s neurologic function.[2]
- Anticonvulsants are administered to the patients who have a seizure. Phenytoin given concurrently with radiation may have serious skin reactions such as erythema multiforme and Stevens-Johnson syndrome.
- Corticosteroids, usually dexamethasone given 4-10 mg every 4-6 h, can reduce peritumoral edema, diminish mass effect, and lower intracranial pressure with a decrease in headache or drowsiness.
References
- ↑ 1.0 1.1 Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T (2010). "Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases". Neurosurg Rev. 34 (2): 197–208. doi:10.1007/s10143-010-0306-1. PMID 21301914.
- ↑ 2.0 2.1 Rajz GG, Nass D, Talianski E, Pfeffer R, Spiegelmann R, Cohen ZR (2012). "Presentation patterns and outcome of gliomatosis cerebri". Oncol Lett. 3 (1): 209–213. doi:10.3892/ol.2011.445. PMC 3362440. PMID 22740882.
- ↑ Hejazi N, Witzmann A, Hergan K (2001). "Gliomatosis cerebri: intra vitam stereotactic determination in two cases and review of the literature". Br J Neurosurg. 15 (5): 396–401. PMID 11708542.
- ↑ Levin N, Gomori JM, Siegal T (2004). "Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide". Neurology. 63 (2): 354–6. PMID 15277636.
- ↑ Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crinò L; et al. (2003). "Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration". Magn Reson Imaging. 21 (9): 1003–7. PMID 14684203.
- ↑ Sanson M, Napolitano M, Cartalat-Carel S, Taillibert S (2005). "[Gliomatosis cerebri]". Rev Neurol (Paris). 161 (2): 173–81. PMID 15798516.
- ↑ Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ; et al. (1980). "Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors". Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
- ↑ Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB; et al. (2002). "Gliomatosis cerebri: molecular pathology and clinical course". Ann Neurol. 52 (4): 390–9. doi:10.1002/ana.10297. PMID 12325066.
- ↑ Qaddoumi I, Kocak M, Pai Panandiker AS, Armstrong GT, Wetmore C, Crawford JR; et al. (2014). "Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas". Front Oncol. 4: 67. doi:10.3389/fonc.2014.00067. PMC 3978340. PMID 24744992.
- ↑ Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE; et al. (1996). "Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas". Neurosurgery. 39 (5): 921–6. PMID 8905746.